Who is eligible for clinical trial NCT07737951?

Participants must meet protocol criteria for Hormone Receptor Positive Breast Carcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07737951 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-12

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia (NCT07737951)

Evaluating Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors

🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Thomas Jefferson University

🩺 Plain-English Summary (8th-Grade Level)

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.

Who can join: Review the eligibility criteria below.

Location: Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania

Age range: 18 Years

🧪 Interventions in This Study

Tai Chi (BEHAVIORAL)
Health Education (BEHAVIORAL)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania

📞 Contact the Study Coordinator

Phone: (215) 503-4623

Email: Kuang-Yi.Wen@Jefferson.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hormone Receptor Positive Breast Carcinoma

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer — Chicago, Illinois

Explore by condition: All Hormone Receptor Positive Breast Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗